Biocon shares rally nearly 6% after unit receives USFDA nod for cancer drug
Biocon's shares surged following USFDA approval for Jobevne, a biosimilar to Avastin, used in treating various cancers. This marks Biocon's seventh biosimilar approval in the U.S., strengthening its oncology portfolio. With bevacizumab sales reaching $2 billion in the U.S. in 2023, this (...)
Site référencé: The Economic Times
The Economic Times
Morgan Stanley slashes Sensex target to 82,000
16/04/2025
Auto and ancillary company shares zoom on tariff reprieve hopes
16/04/2025
In-person discussions likely in May to push India-US trade pact
16/04/2025
ICICI Lombard General Insurance Q4 Results : Net profit slips 2% to Rs 510 crore
15/04/2025
What a $34,000 bag really costs : Chinese suppliers show luxury goods at 90% lower prices amid trade war with US
15/04/2025
Warren Buffett’s son traded his inheritance for time — a fortune that would be worth $500 million today
15/04/2025
